Oyagen, Inc.
Rochester, NY
- UEI
- JDWRVEQGKPJ8
- CAGE
- 5CUE2
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1200 Jefferson Rd Suite 210, Rochester, NY 14623, USA
- Website
- oyageninc.com
- Founded
- 2003
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Nubad LLC | Greer, SC | 541380 Testing Laboratories and Services |
| Emmune Inc. | Cambridge, MA | — |
| Oncotrap Inc. | Chapel Hill, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Autonomous Therapeutics Inc. | Silver Spring, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Novab, Inc. | Tucker, GA | 621511 Medical Laboratories |
About the company
Oyagen, Inc. Oyagen Division - doing business as Oyagen Inc., is a biotechnology company formed in 2003 for the purpose of discovering, developing, and commercializing novel pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. OyaGen offers fee for service assay development and screening.
Through federal grant awards, Oyagen has received funding from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to develop therapeutics for infectious diseases. A recent $299,000 award aims to develop a high-throughput screening assay to identify small molecule antagonists targeting the Ebola virus VP40 protein, with the goal of discovering fast-acting antivirals to enhance survival of Ebola patients. Another $900,000 award funds IND-enabling studies to establish the pharmacokinetics and SARS-CoV-2 antiviral efficacy of sangivamycin in a hamster model, with the objective of developing a COVID-19 therapeutic candidate. Additionally, Oyagen received a $1.1 million grant for the development of lead inhibitors of HIV Vif binding to the antiretroviral A3G protein through medicinal chemistry. These awards demonstrate Oyagen's expertise in drug discovery, assay development, and preclinical studies targeting viral proteins for the treatment of infectious diseases like Ebola, COVID-19, and HIV/AIDS.
SBA capabilities narrative
Assay development for antiviral compounds
Quick answers
Is Oyagen, Inc. registered in SAM.gov?
Yes. Oyagen, Inc.'s SAM.gov registration is active through April 27, 2027.
What is Oyagen, Inc.'s most recent federal award?
Oyagen, Inc.'s most recent federal grant award is High throughput screening and drug discovery for antagonists of the ebola VP40 protein assembly (R43AI179320), from National Institute of Allergy and Infectious Diseases (NIH), on August 10, 2023.
On GovTribe
See Oyagen, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors